RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical corporate excited by growing drugs to focus on high blood pressure and similar comorbidities akin to continual kidney illness (CKD), obstructive sleep apnea (OSA) and different illnesses pushed through dysregulated aldosterone, introduced lately that on March 16, 2026, the Reimbursement Committee of Mineralys’ Board of Administrators granted an inducement inventory choice award protecting 27,920 stocks and an inducement limited inventory unit award protecting 20,940 stocks of Mineralys commonplace inventory to a brand new non-executive worker.
The awards had been granted below Mineralys’ 2025 Employment Inducement Incentive Award Plan, which supplies for the granting of fairness awards to new staff of Mineralys. The choices will vest over a four-year duration, with 25% of the full stocks underlying the choices vesting at the first anniversary of the award’s vesting graduation date, March 16, 2026, and 1/forty eighth of the full stocks underlying the choice vesting following every one-month duration thereafter, topic to endured provider. The limited inventory devices will vest over a four-year duration, with 25% of the stocks vesting on every of the 4 anniversaries of the award’s vesting graduation date, March 16, 2026. The awards had been granted as an inducement subject material to the brand new non-executive worker getting into into employment with Mineralys, in response to Nasdaq List Rule 5635(c)(4).
About Mineralys
Touch:
Investor Members of the family
